Onconova Therapeutics (NASDAQ: ONTX) is a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with primary focus on Myelodysplastic Syndromes, according to the company’s website (see here: www.onconova.com). SNNLive spoke with Ramesh Kumar, President & CEO of Onconova Therapeutics, Inc. at the LD Micro "Main Event" 2016 in Bel Air, CA.
In this video interview, Mr. Kumar and our host discuss the following topics:
- Overview of Onconova Therapeutics, Inc.
- Discusses the company’s target indications
- How what Onconova is developing is different than what is currently available
- Where science was developed
- Clinical development
- Mr. Kumar’s background
For more information about Onconova Therapeutics, Inc., please visit: www.onconova.com
The interview may contain forward-looking statements about Onconova Therapeutics, Inc. See Onconova Therapeutics' periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions